Queisser Pharma: almost 1m-euro turnover

The Romanian representative office of the pharmaceutical manufacturer Queisser Pharma, has budgeted a 0.9 million-euro turnover for this year, 50% more than the results seen in 2006, due to the launch of new products. “We estimate the vitamin, minerals, and natural extracts segments will see the highest increase in Romania, of 20%,” said Teodora Lupan-Caba, country manager of Queisser Pharma Romania. The company came onto the Romanian market in 2002, with its Protefix range of dental prosthesis adhesives, but the company’s operations actually started in 2005 with the launch of nutritional supplements, Doppelherz Aktiv. With these brands Queisser Pharma posted sales worth 0.6 million euros on the domestic market last year. Queisser Pharma’s annual turnover stands at over 100 million euros, and the countries where the company has the highest coverage are Germany, Austria, Russia, Poland, Ukraine and Romania. The most important therapeutic area is the treatment and prevention of cardiovascular diseases. The domestic market of nutritional supplements is estimated at around 45 million euros, with an over 20% annual growth rate. By 2010, market players’ estimates indicate that the market could reach around 80-90 million euros, which would represent almost a doubling against the current level. The main factors behind the growth of this market are the higher levels of competition on a segment that is increasingly more attractive for businesses, and a growing number of consumers who are in the know.